SCHEMBL7673687

SCHEMBL7673687

CN(C)C(CN1CCc2ccc(Cl)cc21)/C(=C/C(=O)O)C(=O)O

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR2A P28223 5/20 0.52
HTR2C P28335 5/20 0.52
HTR2B P41595 5/20 0.52
NOTUM Q6P988 2/20 0.43
LMNA P02545 1/20 0.43
PMP22 Q01453 1/20 0.43
NPSR1 Q6W5P4 1/20 0.43
GFER P55789 1/20 0.43
HDAC1 Q13547 1/20 0.40
HDAC6 Q9UBN7 1/20 0.40
DRD2 P14416 2/20 0.36
DRD4 P21917 1/20 0.36
CYP1A2 P05177 2/20 0.36
CYP3A4 P08684 2/20 0.36
CYP2D6 P10635 2/20 0.36
NFKB1 P19838 1/20 0.36
HIF1A Q16665 1/20 0.36
XIAP P98170 1/20 0.36
BIRC2 Q13490 1/20 0.36
HSD17B3 P37058 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7673508 0.83 HTR2A (0.58) HTR2AHTR2CHTR2BNOTUMLMNA
Fumaric Acid SCHEMBL7676257 0.74 HTR2A (0.81) HTR2AHTR2CHTR2BNOTUMLMNA
Fumaric Acid SCHEMBL7676268 0.74 HTR2A (0.81) HTR2AHTR2CHTR2BNOTUMLMNA
SCHEMBL7673694 0.73 HTR2A (0.54) HTR2AHTR2CHTR2BNOTUMLMNA
Fumaric Acid SCHEMBL7673702 0.73 LMNA (0.51) HTR2AHTR2CHTR2BNOTUMLMNA
Fumaric Acid SCHEMBL7673519 0.72 HTR2A (0.54) HTR2AHTR2CHTR2BNOTUMLMNA
Fumaric Acid SCHEMBL7676265 0.70 HTR2A (0.52) HTR2AHTR2CHTR2BNOTUMLMNA
Fumaric Acid SCHEMBL7673698 0.70 HTR2A (0.52) HTR2AHTR2CHTR2BNOTUMLMNA
SCHEMBL7679545 0.70 LMNA (0.65) HTR2AHTR2CHTR2BLMNAPMP22
SCHEMBL905975 0.69 HTR2A (1.00) HTR2AHTR2CHTR2BNOTUMLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6380238-B1 FOR THERAPY OF DISORDERS OF THE CENTRAL NERVOUS SYSTEM; DAMAGE TO THE CENTRAL NERVOUS SYSTEM; CARDIOVASCULAR DISORDERS; GASTROINTESTINAL DISORDERS; DIABETES INSIPIDUS, AND SLEEP APNEA VERNALIS RESEARCH LIMITED (GB) 2002-04-30 US disclosed
EP-1109784-A1 INDOLINE DERIVATIVES AS 5-HT2B AND/OR 5-HT2C RECEPTOR LIGANDS VERNALIS RESEARCH LIMITED (GB) 2001-06-27 EP disclosed
WO-2000012475-A1 INDOLINE DERIVATIVES AS 5-HT2B AND/OR 5-HT2C RECEPTOR LIGANDS VERNALIS RESEARCH LIMITED (GB) 2000-03-09 WO disclosed